Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

The vaccine candidate is the furthest any shot has gotten since the last one was pulled in 2002. Scientists are testing other ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

A new Lyme disease vaccine made by Pfizer and Valneva could lower infection rates of the tick-borne illness, but federal approval and patient uptake could be a challenge ...

Results from a phase 3 clinical trial of Pfizer’s Lyme disease vaccine candidate found it was more than 70 percent effective at preventing the illness. Participants in Pfizer’s trial received four ...

Pfizer shared an update last week on its clinical trial for VALOR, which is short for "Vaccine Against Lyme for Outdoor Recreationists." The drugmaker said in its report that the vaccine was ...

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though fewer-than-expected cases in a study made it hard to determine how well it works on a ...

(WXYZ) — In today’s Health Alert, Pfizer’s Lyme vaccine shows strong protection in a phase 3 clinical trial, but misses a key study goal. Meanwhile, experts say ...